THE ALTERATION OF IMMUNOPROFILE DURING DASATINIB TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A PROSPECTIVE OBSERVATIONAL STUDY

被引：0
|
作者：
Kuno, M. [1 ]
Nakamae, H. [1 ]
Katayama, T. [1 ]
Nishimoto, M. [1 ]
Hayashi, Y. [1 ]
Hirose, A. [1 ]
Nakamae, M. [1 ]
Nakashima, Y. [1 ]
Koh, H. [1 ]
Nakane, T. [1 ]
Hino, M. [1 ]
机构：
[1] Osaka City Univ, Grad Sch Med, Hematol, Osaka, Japan
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1106
引用
收藏
页码：457 / 457
页数：1
相关论文
共 50 条
  • [1] Immunoprofile of Patients with Chronic Myeloid Leukemia Treated with Imatinib, Nilotinib or Dasatinib
    Hayashi, Yoshiki
    Nakamae, Hirohisa
    Katayama, Takako
    Nakane, Takahiko
    Koh, Hideo
    Nishimoto, Mitsutaka
    Nakamae, Mika
    Yoshida, Masahiro
    Bingo, Masato
    Okamura, Hiroshi
    Aimoto, Mizuki
    Manabe, Masahiro
    Yoshimura, Takuro
    Inaba, Akiko
    Nanno, Satoshi
    Hagihara, Kiyoyuki
    Nakao, Yoshitaka
    Terada, Yoshiki
    Hino, Masayuki
    BLOOD, 2011, 118 (21) : 1607 - 1607
  • [2] Skin lesions in chronic myeloid leukemia patients during dasatinib treatment
    Tarantini, Francesco
    Anelli, Luisa
    Ingravallo, Giuseppe
    Attolico, Immacolata
    Zagaria, Antonella
    Rossi, Antonella Russo
    Lospalluti, Lucia
    Bufano, Tamara
    Zanframundo, Giovanni
    Maiorano, Eugenio
    Specchia, Giorgina
    Albano, Francesco
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 7991 - 7996
  • [3] Dasatinib in the Treatment of Chronic Myeloid Leukemia
    Gora-Tybor, Joanna
    Robak, Tadeusz
    CURRENT SIGNAL TRANSDUCTION THERAPY, 2011, 6 (01) : 99 - 105
  • [4] Dasatinib for the treatment of chronic myeloid leukemia
    Fullmer, Amber
    Kantarjian, Hagop
    Cortes, Jorge
    Jabbour, Elias
    EXPERT REVIEW OF HEMATOLOGY, 2011, 4 (03) : 253 - 260
  • [5] FRONT-LINE TREATMENT OF BCR-ABL plus CHRONIC MYELOID LEUKEMIA WITH DASATINIB: A PROSPECTIVE MULTICENTRIC OBSERVATIONAL STUDY
    Castagnetti, F.
    Gugliotta, G.
    Breccia, M.
    Sora, F.
    Iurlo, A.
    Gozzini, A.
    Scortechini, A. R.
    Luciano, L.
    Stagno, F.
    Malato, A.
    Abruzzese, E.
    Crugnola, M.
    Pregno, P.
    Specchia, G.
    Musto, P.
    Cascavilla, N.
    Tiribelli, M.
    Bonifacio, M.
    Galieni, P.
    Palmieri, F.
    Soverini, S.
    Bochicchio, M. T.
    Sica, S.
    Foa, R.
    Cavo, M.
    Martinelli, G.
    Saglio, G.
    Pane, F.
    Baccarani, M.
    Rosti, G.
    HAEMATOLOGICA, 2017, 102 : 92 - 92
  • [6] An Observational Prospective Study of Dasatinib 50mg Daily As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia Patients in Chronic Phase
    Singh, Reema
    Halder, Rohan
    Kapoor, Jyotsna
    Verma, Megha
    Mehta, Pallavi
    Agrawal, Narendra
    Ahmed, Rayaz
    Bhurani, Dinesh
    BLOOD, 2022, 140 : 12197 - 12199
  • [7] Baseline Characteristics Of Patients With Chronic Myeloid Leukemia In a Prospective Observational Study (SIMPLICITY)
    Cortes, Jorge E.
    Hehlmann, Rudiger
    Gambacorti-Passerini, Carlo
    Goldberg, Stuart
    Khoury, H. Jean
    Mauro, Michael
    Michallet, Mauricette
    Paquette, Ron
    Simonsson, Bengt
    Foreman, Aimee
    Mohamed, Hesham
    Zyczynski, Teresa
    Hirji, Ishan
    Davis, Catherine
    BLOOD, 2013, 122 (21) : 4026 - 4029
  • [8] Dasatinib regimens for patients with chronic myeloid leukemia
    François Guilhot
    Lydia Roy
    Nature Reviews Clinical Oncology, 2009, 6 : 680 - 682
  • [9] Once-Daily Dasatinib for Treatment of Patients with Chronic Myeloid Leukemia
    Tyler, Timothy
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (05) : 920 - 927
  • [10] An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia After Experiencing Pleural Effusion During Dasatinib Therapy
    McBride, Ali
    Brokars, John
    Reddy, Sheila Reiss
    Chang, Eunice
    Tarbox, Marian H.
    LeBlanc, Thomas W.
    ACTA HAEMATOLOGICA, 2023, 146 (04) : 259 - 266
12345